210 related articles for article (PubMed ID: 18425620)
1. Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin2 mutations.
Brockmann K; Dreha-Kulaczewski S; Dechent P; Bönnemann C; Helms G; Kyllerman M; Brück W; Frahm J; Huehne K; Gärtner J; Rautenstrauss B
J Neurol; 2008 Jul; 255(7):1049-58. PubMed ID: 18425620
[TBL] [Abstract][Full Text] [Related]
2. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations.
Chung KW; Kim SB; Park KD; Choi KG; Lee JH; Eun HW; Suh JS; Hwang JH; Kim WK; Seo BC; Kim SH; Son IH; Kim SM; Sunwoo IN; Choi BO
Brain; 2006 Aug; 129(Pt 8):2103-18. PubMed ID: 16835246
[TBL] [Abstract][Full Text] [Related]
3. Early-onset Charcot-Marie-Tooth patients with mitofusin 2 mutations and brain involvement.
Chung KW; Suh BC; Cho SY; Choi SK; Kang SH; Yoo JH; Hwang JY; Choi BO
J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1203-6. PubMed ID: 20587496
[TBL] [Abstract][Full Text] [Related]
4. Large kindred evaluation of mitofusin 2 novel mutation, extremes of neurologic presentations, and preserved nerve mitochondria.
Klein CJ; Kimmel GW; Pittock SJ; Engelstad JE; Cunningham JM; Wu Y; Dyck PJ
Arch Neurol; 2011 Oct; 68(10):1295-302. PubMed ID: 21987543
[TBL] [Abstract][Full Text] [Related]
5. [Mutations in the mitofusin 2 gene are the most common cause of Charcot-Marie-Tooth type 2 disease].
Sołtysińska E; Kabzińska D; Kochański A
Neurol Neurochir Pol; 2007; 41(4):350-4. PubMed ID: 17874344
[TBL] [Abstract][Full Text] [Related]
6. Genetic epidemiology of Charcot-Marie-Tooth disease.
Braathen GJ
Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial GTPase mitofusin 2 mutations in Korean patients with Charcot-Marie-Tooth neuropathy type 2.
Cho HJ; Sung DH; Kim BJ; Ki CS
Clin Genet; 2007 Mar; 71(3):267-72. PubMed ID: 17309650
[TBL] [Abstract][Full Text] [Related]
8. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2.
Züchner S; De Jonghe P; Jordanova A; Claeys KG; Guergueltcheva V; Cherninkova S; Hamilton SR; Van Stavern G; Krajewski KM; Stajich J; Tournev I; Verhoeven K; Langerhorst CT; de Visser M; Baas F; Bird T; Timmerman V; Shy M; Vance JM
Ann Neurol; 2006 Feb; 59(2):276-81. PubMed ID: 16437557
[TBL] [Abstract][Full Text] [Related]
9. Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction.
Del Bo R; Moggio M; Rango M; Bonato S; D'Angelo MG; Ghezzi S; Airoldi G; Bassi MT; Guglieri M; Napoli L; Lamperti C; Corti S; Federico A; Bresolin N; Comi GP
Neurology; 2008 Dec; 71(24):1959-66. PubMed ID: 18946002
[TBL] [Abstract][Full Text] [Related]
10. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.
Baloh RH; Schmidt RE; Pestronk A; Milbrandt J
J Neurosci; 2007 Jan; 27(2):422-30. PubMed ID: 17215403
[TBL] [Abstract][Full Text] [Related]
11. Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2.
McCorquodale DS; Montenegro G; Peguero A; Carlson N; Speziani F; Price J; Taylor SW; Melanson M; Vance JM; Züchner S
J Neurol; 2011 Jul; 258(7):1234-9. PubMed ID: 21258814
[TBL] [Abstract][Full Text] [Related]
12. A cohort study of MFN2 mutations and phenotypic spectrums in Charcot-Marie-Tooth disease 2A patients.
Choi BO; Nakhro K; Park HJ; Hyun YS; Lee JH; Kanwal S; Jung SC; Chung KW
Clin Genet; 2015 Jun; 87(6):594-8. PubMed ID: 24863639
[TBL] [Abstract][Full Text] [Related]
13. A cohort study of Han Chinese MFN2-related Charcot-Marie-Tooth 2A.
Lv H; Wang L; Zhang W; Wang Z; Zuo Y; Liu J; Yuan Y
J Neurol Sci; 2015 Nov; 358(1-2):153-7. PubMed ID: 26382835
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the phenotypic manifestations of MFN2 R104W mutation in Charcot-Marie-Tooth type 2.
Genari AB; Borghetti VH; Gouvêa SP; Bueno KC; dos Santos PL; dos Santos AC; Barreira AA; Lourenço CM; Marques W
Neuromuscul Disord; 2011 Jun; 21(6):428-32. PubMed ID: 21531138
[TBL] [Abstract][Full Text] [Related]
15. Phenotype of Charcot-Marie-Tooth disease Type 2.
Bienfait HM; Baas F; Koelman JH; de Haan RJ; van Engelen BG; Gabreëls-Festen AA; Ongerboer de Visser BW; Meggouh F; Weterman MA; De Jonghe P; Timmerman V; de Visser M
Neurology; 2007 May; 68(20):1658-67. PubMed ID: 17502546
[TBL] [Abstract][Full Text] [Related]
16. Clinical and allelic heterogeneity in a pediatric cohort of 11 patients carrying MFN2 mutation.
Di Meglio C; Bonello-Palot N; Boulay C; Milh M; Ovaert C; Levy N; Chabrol B
Brain Dev; 2016 May; 38(5):498-506. PubMed ID: 26686600
[TBL] [Abstract][Full Text] [Related]
17. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features.
Bombelli F; Stojkovic T; Dubourg O; Echaniz-Laguna A; Tardieu S; Larcher K; Amati-Bonneau P; Latour P; Vignal O; Cazeneuve C; Brice A; Leguern E
JAMA Neurol; 2014 Aug; 71(8):1036-42. PubMed ID: 24957169
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A.
Kijima K; Numakura C; Izumino H; Umetsu K; Nezu A; Shiiki T; Ogawa M; Ishizaki Y; Kitamura T; Shozawa Y; Hayasaka K
Hum Genet; 2005 Jan; 116(1-2):23-7. PubMed ID: 15549395
[TBL] [Abstract][Full Text] [Related]
19. Diffusion tensor imaging and magnetic resonance spectroscopy of transient cerebral white matter lesions in X-linked Charcot-Marie-Tooth disease.
Sato K; Kubo S; Fujii H; Okamoto M; Takahashi K; Takamatsu K; Tanaka A; Kuriyama M
J Neurol Sci; 2012 May; 316(1-2):178-80. PubMed ID: 22341131
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults.
Ouvrier R; Grew S
Dev Med Child Neurol; 2010 Apr; 52(4):328-30. PubMed ID: 20163430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
